February 27, 2017 / 13:26 IST
We expect APL’s revenues/EBIDTA/net profit to grow at a CAGR of 17%/20%/23% over the next three years. We further expect its EBIDTA margin to improve 220bps to 25.1% from 22.9% over the same period. The overall growth would be driven by the strong growth in the US market, new ANDA approvals, entry into new geographies and new therapeutic segments.
Outlook
We maintain our Buy rating on Aurobindo Pharma (APL), with a TP of Rs 1,110 based on 18x March’19E EPS of Rs61.7. Our detailed analysis of APL’s annual reports from FY11-FY16 reveals that the company is poised for strong growth due to its global footprint spanning 150 countries, well diversified product basket, and strong product pipeline.
For all recommendations, click here Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions. 
Read More
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
